[go: up one dir, main page]

CN115996923A - 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 - Google Patents

一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 Download PDF

Info

Publication number
CN115996923A
CN115996923A CN202180052880.5A CN202180052880A CN115996923A CN 115996923 A CN115996923 A CN 115996923A CN 202180052880 A CN202180052880 A CN 202180052880A CN 115996923 A CN115996923 A CN 115996923A
Authority
CN
China
Prior art keywords
alkyl
halogen
hydroxy
cyano
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052880.5A
Other languages
English (en)
Inventor
李瑶
石宗军
张国彪
陈雷
王文晶
张晓波
郑登宇
徐波
刘鑫
王亚军
叶飞
唐平明
倪佳
张晨
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haisco Pharmaceutical Group Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN115996923A publication Critical patent/CN115996923A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

提供一种式(I)所示的腈衍生物化合物，其立体异构体、氘代物、共晶、溶剂化物或药学上可接受的盐，各基团如说明书之定义。所述化合物具有二肽基肽酶1抑制活性，可用于制备治疗包括气道阻塞性疾病、支气管扩张、囊性纤维化、哮喘、肺气肿和慢性阻塞性肺病等疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202180052880.5A 2020-08-26 2021-08-25 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 Pending CN115996923A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010871912 2020-08-26
CN2020108719121 2020-08-26
CN2020111298096 2020-10-21
CN202011129809 2020-10-21
CN2021101677315 2021-02-07
CN202110167731 2021-02-07
PCT/CN2021/114500 WO2022042591A1 (zh) 2020-08-26 2021-08-25 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途

Publications (1)

Publication Number Publication Date
CN115996923A true CN115996923A (zh) 2023-04-21

Family

ID=80354645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052880.5A Pending CN115996923A (zh) 2020-08-26 2021-08-25 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途

Country Status (24)

Country Link
US (2) US11807635B2 (zh)
EP (2) EP4497473A2 (zh)
JP (1) JP7657291B2 (zh)
KR (1) KR20230084134A (zh)
CN (1) CN115996923A (zh)
AU (1) AU2021330865B2 (zh)
BR (1) BR112023003492A2 (zh)
CA (1) CA3190610A1 (zh)
CL (1) CL2023000532A1 (zh)
DK (1) DK4129989T3 (zh)
ES (1) ES3008541T3 (zh)
FI (1) FI4129989T3 (zh)
HR (1) HRP20241656T1 (zh)
HU (1) HUE069470T2 (zh)
IL (1) IL300855A (zh)
LT (1) LT4129989T (zh)
MX (1) MX2023002371A (zh)
PL (1) PL4129989T3 (zh)
PT (1) PT4129989T (zh)
RS (1) RS66302B1 (zh)
SI (1) SI4129989T1 (zh)
SM (1) SMT202400510T1 (zh)
TW (1) TW202214616A (zh)
WO (1) WO2022042591A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
WO2022042591A1 (zh) * 2020-08-26 2022-03-03 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN116783189A (zh) * 2021-02-05 2023-09-19 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
EP4484423A1 (en) * 2022-02-22 2025-01-01 Haisco Pharmaceuticals Pte. Ltd. Preparation method of nitrogen-containing heterocyclic compound
AU2023225835A1 (en) * 2022-02-22 2024-10-03 Haisco Pharmaceuticals Pte. Ltd. Salt and crystal form of dipeptidyl peptidase inhibitor compound
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
WO2024173556A2 (en) * 2023-02-15 2024-08-22 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
WO2024192416A1 (en) * 2023-03-16 2024-09-19 Insmed Incorporated Dpp1 inhibitors with polycyclic linkers and uses thereof
TW202442238A (zh) * 2023-03-23 2024-11-01 大陸商西藏海思科製藥有限公司 二肽基肽酶小分子抑制劑的藥物组合物
WO2025056038A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945851A (zh) * 2007-12-12 2011-01-12 阿斯利康(瑞典)有限公司 肽基腈和其作为二肽基肽酶i抑制剂的用途
CN105980367A (zh) * 2014-01-24 2016-09-28 阿斯利康(瑞典)有限公司 (2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧杂氮杂环庚烷-2-甲酰胺作为二肽基肽酶i抑制剂
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
BR0214642A (pt) 2001-12-04 2004-11-03 Hoffmann La Roche Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
JP2006527704A (ja) 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
JP2012526093A (ja) 2009-05-07 2012-10-25 アストラゼネカ・アクチエボラーグ 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
JP5815542B2 (ja) * 2009-10-29 2015-11-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｄｐｐ−１阻害剤として有用なアルキニル誘導体
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2014140078A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
WO2015032942A1 (en) * 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
WO2016139355A1 (en) * 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EP3342765B1 (en) 2015-08-29 2021-09-15 Sunshine Lake Pharma Co., Ltd. Cathepsin k inhibitor and application thereof
WO2022042591A1 (zh) * 2020-08-26 2022-03-03 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945851A (zh) * 2007-12-12 2011-01-12 阿斯利康(瑞典)有限公司 肽基腈和其作为二肽基肽酶i抑制剂的用途
CN105980367A (zh) * 2014-01-24 2016-09-28 阿斯利康(瑞典)有限公司 (2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧杂氮杂环庚烷-2-甲酰胺作为二肽基肽酶i抑制剂
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEVIN DOYLE, ET AL.: ""Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)"", 《J. MED. CHEM.》, vol. 59, 2 October 2016 (2016-10-02), pages 9457, XP093001290, DOI: 10.1021/acs.jmedchem.6b01127 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途

Also Published As

Publication number Publication date
ES3008541T3 (en) 2025-03-24
WO2022042591A1 (zh) 2022-03-03
US11807635B2 (en) 2023-11-07
EP4129989A4 (en) 2024-06-05
FI4129989T3 (fi) 2024-12-16
TW202214616A (zh) 2022-04-16
JP7657291B2 (ja) 2025-04-04
PL4129989T3 (pl) 2025-02-24
RS66302B1 (sr) 2025-01-31
AU2021330865B2 (en) 2024-07-18
BR112023003492A2 (pt) 2023-05-09
EP4129989A1 (en) 2023-02-08
MX2023002371A (es) 2023-05-19
PT4129989T (pt) 2024-12-17
KR20230084134A (ko) 2023-06-12
CA3190610A1 (en) 2022-03-03
CL2023000532A1 (es) 2023-09-29
US20230121807A1 (en) 2023-04-20
LT4129989T (lt) 2024-12-27
DK4129989T3 (da) 2024-12-02
HRP20241656T1 (hr) 2025-02-14
EP4497473A2 (en) 2025-01-29
HUE069470T2 (hu) 2025-03-28
JP2023539101A (ja) 2023-09-13
US20240059681A1 (en) 2024-02-22
EP4129989B1 (en) 2024-10-02
IL300855A (en) 2023-04-01
AU2021330865A1 (en) 2023-04-27
SMT202400510T1 (it) 2025-01-14
SI4129989T1 (sl) 2025-03-31
AU2021330865A9 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
CN115996923A (zh) 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
US9988390B2 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
RU2014131014A (ru) Димерные соединения-агонисты рецептора fgf (fgfr), способ их получения и их терапевтическое применение
JP2010540593A5 (zh)
JP2007505931A5 (zh)
JP2009526831A5 (zh)
JP5902172B2 (ja) 広範囲のインフルエンザ抗ウイルス薬としての新規ピペラジン類似体
JPWO2020123827A5 (zh)
JP5833143B2 (ja) フェニル−イソオキサゾール誘導体およびその製造方法
CN111303147A (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN102746292A (zh) 环化的小檗碱衍生物及其制备方法和用途
CN102131803A (zh) (1r，2s，3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1，2，3，4-四醇的固体形式及其使用方法
JP2018065817A (ja) 抗ウイルス活性を有するメタンチオン化合物
CN105121433B (zh) 抗病毒化合物、其药学上可接受的盐或光学异构体、用于制备它们的方法以及包含它们作为有效成分的用于预防或治疗病毒性疾病的药物组合物
CN102603553B (zh) 具有协同抗真菌作用的化合物及其在药学中的用途
WO2019191502A4 (en) Compounds for treatment of cardiac arrhythmias and heart failure
CA2502833A1 (en) Quaternary ammonium compounds and their use as antimuscarinic agents
JP3426242B2 (ja) ジアザシクロアルカンアルキルスルホンアミド誘導体
JP6826986B2 (ja) ウィルス性疾患の治療に有用なイミノ糖類
US20190077798A1 (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
CN110478344B (zh) 一种酰基硫脲类化合物在制备抗乙型流感病毒药物中的应用
US20220127220A1 (en) Compounds and methods for treating influenza
KR101070176B1 (ko) Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물
CZ453699A3 (cs) Způsob a meziprodukty pro přípravu inhibitorů 5-lipoxygenasy
CN115304502B (zh) Foxm1抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088676

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20231213

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: 611130 No.136 Baili Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province

Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250102

Address after: No.17 Sanxiang Avenue, Zedang Town, Shannan City, Tibet Autonomous Region

Applicant after: HAISCO PHARMACEUTICAL Group Inc.

Country or region after: China

Address before: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant before: Tibet Haisike Pharmaceutical Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right